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Abstract
Posaconazole (PSC) is currently recommended as primary prophylaxis in neutropenic patients with acute myeloid leukaemia (AML) and in
allogenic haematopoietic stem cell transplantation (AHSCT) recipients with graft-versus-host disease (GVHD). Studies focusing on
breakthrough invasive fungal disease (IFD) upon PSC prophylaxis show disparate results. In order to evaluate the incidence of IFD in
patients on PSC prophylaxis and identify IFD risk factors, we carried out a retrospective study of all consecutive patients on PP from January
2007 to December 2010 in our hospital. Breakthrough IFDs were identiﬁed from the database of the central pharmacy and the French
administrative database (PMSI), registering ﬁnal medical diagnoses of hospitalized patients. Medical data were reviewed to study proven or
probable IFD, according to EORTC/MSG deﬁnition. PSC plasma concentrations (PPC) were also retrieved. Poisson models were used for
statistical analysis. Two hundred and seventy-nine patients received PSC prophylaxis for a median duration of 1.4 months (range 0.2–17.9).
Proven (n = 6) or probable (n = 3) IFDs were diagnosed in nine cases (3.2%). IFD incidence rate per 100 person-month was 1.65 (95% CI,
0.79–2.97). IFDs were candidaemia (Candida glabrata, n = 2), pulmonary invasive aspergillosis (n = 3), disseminated fusariosis (n = 2) and
pulmonary mucormycosis (n = 2). Seven deaths were reported, directly related to IFD in three patients (33.3%). First dosage of PPC under
0.3 mg/L was the single signiﬁcant risk factor for IFD (RR, 7.77; 95% CI, 1.30–46.5; p 0.025). Breakthrough IFD in patients receiving PSC
prophylaxis is rare but associated with a poor outcome. Low PSC plasma concentrations are associated with an increased risk of IFD.
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Introduction
Despite improvement in the management of acute leukaemia
(AL) and allogenic haematopoietic stem cell transplantation
(AHSCT), invasive fungal infection (IFD) remains an important
cause of morbidity and mortality in these settings [1,2].
Identiﬁed risk factors for IFD, such as prolonged and profound
neutropenia, corticosteroids and immunosuppressive
therapies, recent surgery, exposure to invasive devices,
broad-spectrum antibiotic therapy, older age, diabetes mell-
itus, renal failure, viral infections and fungal colonization, are
often combined in patients with haematological malignancies
[3]. A poor outcome is often described during the course of
IFD [2,4–6]. Primary prophylaxis using ﬂuconazole has been
proven to prevent Candida infections and to reduce mortality
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in patients with haematological cancers [7]. With ﬂuconazole
prophylaxis, the incidence of candidaemia has declined, but an
increase of bloodstream infections due to non-albicans Candida
species, including ﬂuconazole-resistant C. glabrata and C. kru-
sei, has been reported [8]. Aspergillus spp. and other moulds,
including zygomycetes and Fusarium spp., have become more
frequent causes of IFD [2,5,9]. New agents were subsequently
developed for IFD prophylaxis, such as posaconazole (PSC),
which was demonstrated to be superior to ﬂuconazole for IFD
prevention in two large controlled trials [10,11] and is
currently recommended as primary prophylaxis for patients
with acute myeloid leukaemia (AML) and chemother-
apy-induced neutropenia and for AHSCT recipients with
graft-versus-host disease (GVHD).
Posaconazole is an extended-spectrum triazole, with potent
antifungal activity against most Candida spp., Aspergillus spp.,
Fusarium spp., mucormycetes and endemic fungi [12]. Thera-
peutic drug monitoring is advocated as inter- and intra-vari-
ability in absorption might affect drug efﬁcacy [13].
Breakthrough IFD during the exposure period of PSC
prophylaxis was reported in 2% of neutropenic patients [10]
and 2.4% of AHSCT recipients [11] in the two pivotal
controlled trials. However, other studies show disparate
results, with IFD incidence varying from 0 to 17% [14–22].
The principal aim of our study was to investigate in the
‘real-life’ setting the incidence of breakthrough IFD occurring
in patients with haematological cancers receiving PSC primary
prophylaxis. Secondary objectives were to identify risk
factors for breakthrough IFD, and to describe clinical,
microbiological and radiological features of IFD and their
outcome.
Material and Methods
We conducted a retrospective study in which we reviewed the
medical records of all adult patients consecutively treated by
PSC as primary prophylaxis at the Ho^pital Saint-Louis from
January 2007 to December 2010. Saint-Louis Hospital is a
650-bed tertiary hospital with major clinical activities in
haematology. Adult patients with AML, GVHD following
AHSCT, idiopathic aplastic anaemia or myelodysplastic syn-
drome were included if they received antifungal primary
prophylaxis with PSC for at least 7 days.
Patients treated with systemic antifungal agents (PSC,
liposomal amphotericin-B, caspofungin or voriconazole) at
our institution were identiﬁed from the computerized
database of the central pharmacy, as these drugs are
provided using restrictive nominative formularies both for
hospitalized patients and outpatients (in France, PSC is only
available through hospital pharmacies). Physicians have to
provide the reason for PSC prescription on this form (either
prophylaxis or curative treatment). Patients treated with
PSC and subsequently with another systemic antifungal agent
or maintained on PSC as a curative treatment for a
suspected IFD were studied to detect breakthrough IFD.
Breakthrough IFD was deﬁned as occurrence of a proven or
probable IFD according to EORTC/MSG revised deﬁnitions
[21] while on PSC prophylaxis (PP) or within 15 days after
discontinuation of PP. Medical charts were retrieved to
assess indication for PSC treatment and to conﬁrm that
subsequent systemic antifungal agents were used for treating
proven or probable IFD. In order to complete the database,
this ﬁrst list was cross-matched with the electronic medical
record-based information that codes medical activity and
patients’ diagnoses. All patients treated with PSC, and for
whom a coding for ‘opportunistic mycoses’ was notiﬁed,
were studied. For patients still receiving PSC at the end of
2010, follow-up was continued for up to 4 additional
months.
Data recorded were: demographics, underlying haemato-
logical disease and phase of the disease, date of PSC
prophylaxis initiation and discontinuation, and PSC plasma
concentrations (PPCs) on the ﬁfth day of treatment or after.
Cumulated duration of PSC prophylaxis was calculated by
adding duration of all courses of PSC prophylaxis. In the case
of IFD, additional data were studied: clinical presentation,
biological data, chest computed tomography scan (CT), direct
and indirect mycological diagnosis, treatment of IFD and
outcome.
Prophylactic PSC was orally administered at the recom-
mended daily dose of 600 mg, ideally with high-fat meals, acid
beverage or enteric feedings. Galactomannan blood index was
measured systematically once a week in the bone marrow
transplantation unit and chest computed tomography (CT) was
performed before the transplantation. No routine diagnostic
procedure was performed in other units unless an IFD was
suspected. IFD onset was deﬁned as the day of occurrence of
new clinical or radiology symptoms. Neutropenia was deﬁned
as an absolute leukocyte count <1000/mm3 and/or neutrophil
count <500/mm3. When possible, bronchoscopy was per-
formed in the case of suspected pulmonary infection. Bronchial
aspirate and bronchoalveolar lavage (BAL) were analysed for
bacteria, viruses, parasites and fungal pathogens.
Galactomannan antigen was detected using a sandwich immu-
nocapture ELISA (Platelia Aspergillus, Bio-Rad, Marne la
Coquette, France). If there was suspicion of IFD, it was
measured in the serum. Results were expressed as an index of
positivity and were considered positive if ≥0.5 in the serum,
according to the manufacturer’s recommendations. The min-
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imal inhibitory concentrations (MICs) of azole were deter-
mined according to the Antifungal Susceptibility Testing
Subcommittee of the European Committee on Antimicrobial
Susceptibility Testing (AFST-EUCAST) deﬁnitive document
[22]. Plasma concentrations of PSC (PPC) were quantiﬁed as
described previously [23]. The limit of quantiﬁcation was set at
0.05 mg/L. PPC was expected to be above 0.5 mg/L, according
to local recommendations. This threshold and the ﬁrst IQR of
PPC were studied for the risk factor analysis. At the time of
the study, there was no formal protocol to monitor PPC in our
institution. However, a comment was systematically added by
the pharmacist to the results of the PPC, encouraging the
prescribers to increase the doses of PSC when the PPC was
low, to check adherence and to look for potential absorption
issues.
Data were presented as mean (standard deviation), median
(range) or count (per cent). The incidence rate of IFD and
potential risk factors were analysed using Poisson models
accounting for duration of exposure (i.e. cumulated duration
of PSC prophylaxis until IFD or end of treatment for each
patient). Analyses were carried out using the R statistical
software version 2.15.2 (The R Foundation for Statistical
Computing, Vienna, Austria).
Results
From January 2007 to December 2010, 354 patients treated
for haematological cancer received PSC according to the
computerized database of the central pharmacy (Fig. 1).
Among these patients, 84 were excluded because they
received PSC for <7 days (n = 29), for curative treatment
(n = 44), for secondary prophylaxis (n = 2) or while being
treated for another underlying disease (n = 9). Finally, 270
patients (122 women) received PSC as primary prophylaxis
and were included in this study (Table 1). The mean age was
48.6 years (range, 19–87 years). One hundred and sixty-eight
patients (62.2%) were treated with high-dose chemotherapy
for acute myeloid leukaemia and 96 (35.6%) were treated for
GVHD following an AHSCT. Median PSC treatment duration
was 1.4 months (range, 0.2–17.9). One hundred and for-
ty-eight patients (54.8%) had at least one PPC test. Among
these patients, the median number of PPCs was two (IQR, one
to three). Thirty-one patients (20.9%) had a ﬁrst PPC under
0.3 mg/L, and 35 (23.6%) had a ﬁrst PPC between 0.3 and
0.5 mg/L.
While on PSC primary prophylaxis, 40 patients (14.8%)
switched to another antifungal therapy (AFT) because an IFD
was suspected. No patients were maintained on PSC as a
curative treatment for a suspected IFD. Clinical charts of all
these patients were reviewed to conﬁrm or exclude proven or
probable breakthrough IFD. Among these 40 patients, 31 were
excluded from the analysis for the following reasons: PSC
stopped for more than 15 days, n = 20; no IFD, n = 6;
possible IFD, n = 4; missing data, n = 1 (Fig. 1). Finally, proven
(n = 6) or probable (n = 3) breakthrough IFD was diagnosed
in nine cases (3.3%). The incidence rate of IFD per 100
person-month during PSC prophylaxis was 1.68 (95% CI, 0.81–
3.03). All patients were still on PSC prophylaxis at the onset of
IFD. No IFD was diagnosed during the four additional months
PSC treatment
n = 354
PSC as primary prophylaxis for AML, 
GVHD following AHSCT, IAA or MDS
n = 270
Patients excluded
from the analysis
n = 84
IFD suspicion 
n = 40
No breakthrough IFD
n = 31
Reasons for exclusion:
PSC as curative treatment, n = 44
PSC < 7days, n = 29 
PSC as secondary prophylaxis, n = 2
Other underlying disease, n = 9
Reasons for exclusion:
PSC stopped > 15 days before IFD onset, 
n = 20
No IFD, n = 6
Possible IFD, n = 4
Missing data, n = 1
Breakthrough proven
or probable IFD 
n = 9
FIG. 1. Study ﬂow-chart of patients
included in the study. PSC, posaconazole;
AML, acute myeloid leukaemia; GVHD,
graft-versus-host disease; AHSCT,
allogenic haematopoietic stem cell
transplantation; IAA, idiopathic aplastic
anaemia; MDS, myelodysplastic
syndrome; IFD, invasive fungal infection.
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of follow-up in the patients on PSC prophylaxis at the end of
2010. No additional cases were found with the database that
coded patients’ diagnoses.
Patients with breakthrough IFD are described in Table 2;
55.6% were male and the median age was 47 years (range, 18–
65). Underlying diseases or conditions were AML (n = 7, 7/7
on induction therapy), acquired aplastic anaemia (n = 1) and
GVHD following allogenic blood transplantation (n = 1). All
patients had a central venous catheter and received broad
spectrum antibiotics in the month before the onset of IFD. All
except one patient (an AHSCT recipient) were neutropenic at
the onset of IFD. Median duration of neutropenia before the
onset of IFD was 17 days (range, 10–31). The nadir value of
absolute neutrophil count was <100/mm3 in all patients. Total
lymphocyte count at the time of IFD in the AHSCT recipient
with GVHD was 300/mm3.
Invasive fungal diseases were candidaemia (C. glabrata,
n = 2), pulmonary aspergillosis (n = 3), disseminated fusariosis
(n = 2) and pulmonary mucormycosis (n = 2). Amongst the
six patients with positive mycological culture, ﬁve isolates
were tested for susceptibility to antifungal agents and four out
of ﬁve isolates had high MIC to PSC, including both Candida
isolates. Liposomal amphotericin B was the most common
ﬁrst-line antifungal treatment (eight out of nine patients).
Median duration of PSC prophylaxis at IFD onset was 18 days
(range, 7–126).
Posaconazole plasma concentration could be retrieved in
seven patients. The ﬁrst PPC sample was retrieved 10 days
or more after PSC initiation in four out of seven patients
(median, 10 days; range, 6–17). Median ﬁrst PPC was
0.35 mg/L (IQR, 0.18–0.54). The ﬁrst PPC was under
0.5 mg/L in ﬁve patients (71.4%), among whom three patients
(42.9%) had a ﬁrst PPC under 0.3 mg/L. In two of these last
three patients (P4 and P7) the daily dose of PSC had been
increased from 600 to 900 mg because the ﬁrst PPC was
under 0.3 mg/L while on a 600 mg daily regimen. The second
PPC sample was higher in these two patients (respectively,
0.76 and 0.46 mg/L) but IFD had already occurred by this
time. Strikingly, the ﬁrst PPC was performed late after the
initiation of PP in these two patients; respectively, after 14
and 17 days of prophylaxis. Four patients (44.4%) were
treated by proton pump inhibitor, which might have an
impact on PSC absorption. Two patients (22%) had diarrhoea
and one had mucositis (11%) the week before IFD onset.
Median duration of follow-up after IFD was 5 months
(range, 1–36). Five patients were cured at the end of the
curative antifungal therapy, one had improved but died of
refractory AML, and three died because of severe IFD (two
with proven or probable aspergillosis and one with dissemi-
nated fusariosis). Four additional non-IFD-related deaths were
reported. One patient with candidaemia experienced a relapse
of candidaemia 2 months after the ﬁrst episode, while on PSC
secondary prophylaxis.
Compared with patients on PSC prophylaxis who did not
experience IFD, the single signiﬁcant risk factor was a ﬁrst
PPC<0.3 mg/L (RR, 7.90; 95% CI, 1.32–47.3; p 0.024; Table 3).
The prevalence of breakthrough IFD was higher among
leukaemic patients on induction chemotherapy than among
AHSCT recipients with GVHD (4.2 vs. 1%; p 0.058), but the
difference did not reach statistical signiﬁcance. No signiﬁcant
difference in the incidence of IFD was found between patients
who had PPC testing (n = 148/270; 54.8%) and others (RR,
1.93; 95% CI, 0.40–9.29; p 0.41).
Discussion
Breakthrough proven or probable IFD in 270 patients
receiving PSC prophylaxis occurred in 3.3% of cases in this
4-year retrospective study, in 4.2% of neutropenic patients
TABLE 1. Characteristics of the patients on PSC primary prophylaxis and of PSC plasma concentration testing (PPC)
Characteristics
All
n = 270
IFD
n = 9
No IFD
n = 261
Age, mean (SD) years 48.6 (14.5) 45.9 (15.3) 48.7 (14.5)
Women, no. (%) 122 (45.2) 4 (44) 118 (45.2)
Disease, no. (%)
AML 168 (62.2) 8 (89) 160 (61.3)
GVHD following AHSCT 96 (35.6) 1 (11) 95 (36.4)
IAA 4 (1.5) 0 4 (1.5)
MDS 2 (0.7) 0 2 (0.8)
PSC prophylaxis duration, median (range) months 1.4 (0.2–17.9) 0.7 (0.2–7.4) 1.4 (0.2–17.9)
Number of patients with PPC testing, no. (%) 148 (54.8) 7 (78) 141 (54)
Median number of tests (IQR) 2 (1–3) 2 (1–2) 2 (1–3)
First PPC, median (IQR) mg/L 0.57 (0.32–0.86) 0.35 (0.18–0.54) 0.60 (0.34–0.88)
First PPC<0.3 mg/L, no. (%) 31 (20.9) 3 (43) 28 (19.9)
First PPC ≥ 0.3 and <0.5 mg/L, no. (%) 35 (23.6) 2 (29) 33 (23.4)
Median of all PPCs, median (IQR) mg/L 0.60 (0.36–0.86) 0.43 (0.27–0.71) 0.60 (0.36–0.87)
Last PPC before IFD, median (IQR) mg/L 0.43 (0.35–0.57)
IFD, invasive fungal disease; SD, standard deviation; AML, acute myeloid leukaemia; GVHD, graft-versus-host disease; AHSCT, allogenic haematopoietic stem cell transplantation;
IAA, idiopathic aplastic anaemia; MDS, myelodysplastic syndrome; PSC, posaconazole; PPC, PSC plasma concentration.
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with AML and 1% of AHSCT recipients. These results are
consistent with the two randomized clinical trials that found
a 2% incidence rate in neutropenic patients [10] and 2.4% in
AHSCT recipients [11], and suggest that breakthrough IFD
is also rare in real-life conditions in patients with standard
follow-up. A recent study found also a 3.8% incidence of
probable and proven IFD in 260 leukaemic patients on PSC
prophylaxis [24]. Several observational studies focused on
routine use of PSC prophylaxis and found breakthrough IFD
rates ranging from 0 to 17% [14–22]. These discrepancies
might be explained by the number of patients studied (most
of the time <100), a shorter or no minimal duration of PSC
prophylaxis (although steady state is usually achieved
between 5 and 7 days of treatment) and less stringent IFD
diagnosis criteria (possible IFD was not included in our
study). They may also reﬂect the heterogeneity of patients,
chemotherapy and transplantation practices, IFD diagnostic
modalities and PPC monitoring.
Four out of the nine breakthrough IFD cases (45%) in our
study were mucormycosis or fusariosis, whereas these
diseases only accounted for <20% of IFD in patients with
haematological disease and AHSCT recipients according to
observational studies performed before PSC was widely used
as primary prophylaxis [1,2,5], and in the two pivotal
randomized trials of PSC prophylaxis [10,11]. Similarly, a
recent Austrian retrospective study reported six cases of
mucormycosis among 11 proven IFDs occurring in 95 patients
on PSC prophylaxis [16]. Limited efﬁcacy of PSC for Rhizopus
spp., Rhizomucor spp. and some species of Fusarium [12] might
explain these ﬁndings. Concerns have been raised about an
eventual shift of the IFD spectrum towards uncommon moulds
since the use of PSC prophylaxis, but data are still limited and,
as IFDs are rare events even in haematological settings, it is
difﬁcult to have solid evidence of a signiﬁcant increase in the
incidence of mucormycosis and fusariosis. In our study, a high
proportion of isolates had high MIC to PSC, which suggests a
selection of resistant fungi by PSC prophylaxis. As in the
literature, IFD-related deaths were common in our study and
occurred in patients with aspergillosis and fusariosis.
We found that a PPC <0.3 mg/L was associated with a
signiﬁcant increased risk of IFD (RR, 7.90; 95% CI, 1.32–
47.3; p 0.024). In some patients, the ﬁrst PPC testing was
performed late, 10 days or more after PSC initiation, and
we could postulate that some breakthrough IFD might have
been prevented by monitoring PPC earlier and targeting a
higher level of PPC. Several studies suggest also that low
PSC plasma concentrations are associated with an increased
risk of IFD [14,15]. However, a French study did not detect
any breakthrough IFD among 36 patients on PSC prophy-
laxis, despite a low PPC (<0.5 mL) in 44% of cases [25].T
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Anyway, accurate target concentrations for PSC prophylaxis
remain controversial. PSC bioavailability is highly variable and
depends on several factors: concomitant high-fat meals and
acid beverages enhance PSC plasma concentrations, whereas
diarrhoea, mucitis and several medications such as anti-acid
proton pump inhibitors might reduce PSC absorption
[15,25–27]. For all these reasons, therapeutic drug mon-
itoring is advocated by most authors [15,25,28], even if the
plasma concentration imperfectly reﬂects what happens in
infected tissues [29]. Other risk factors for IFD in patients
on PSC prophylaxis might inﬂuence the effectiveness of PSC
prophylaxis: increased age and lack of response to induction
chemotherapy, as reported by a monocentric prospective
study [30], or genetic variants, as suggested by several
studies (review in Ref. [31]).
Our study has some limitations. The retrospective and
single-centre design of this study could have underestimated
the incidence of IFD among patients on PSC prophylaxis.
Indeed, some patients could have been diagnosed and treated
for a breakthrough IFD in another hospital, or could have
died due to another reason while having an undiagnosed
breakthrough IFD. Moreover, our study had limited power to
identify IFD risk factors, because of the small number of
patients with breakthrough IFD. In addition, the phase of the
disease at the time of PSC prophylaxis was not described in
patients without IFD, whereas we acknowledge that it would
have been relevant information. The occurrence of IFD
before initiation of PSC prophylaxis in patients treated for
AML is very unlikely as PSC is usually initiated within days
after the occurrence of neutropenia, but we can not
absolutely rule out a baseline IFD in these patients. Last,
not all patients had PPC testing, but no signiﬁcant difference
in the incidence of IFD was found between patients who had
PPC testing and others.
In conclusion, these data demonstrate that IFD is rare in
patients on PSC prophylaxis in real-life conditions, but is
associated with a poor outcome. A high frequency of
PSC-resistant fungi amongst breakthrough IFDs is suggested
by our results. In our study, a PPC below 0.3 mg/L was
associated with a signiﬁcant increased risk of IFD, supporting
the usefulness of therapeutic drug monitoring. We suggest
that, in the case of a low PPC, prompt actions in order to
increase PPC should be initiated: optimization of adherence
to treatment, avoidance of drug interactions, administration
with ‘fatty meals’, and/or increasing PSC dosage, in addition
to closer PPC monitoring. New PSC galenics (i.e. intrave-
nous formulations and oral tablets) may help to improve
adherence to PSC treatment and PSC absorption, and thus
to optimize the effectiveness of antifungal prophylaxis in
high-risk haematological patients. Further larger studies are
needed to identify speciﬁc risk factors for IFD in patients on
PSC prophylaxis, and to deﬁne the optimal PSC plasma
concentration.
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